No products in the cart.
Pre-made Romilkimab benchmark antibody ( Bispecific Dual Variable Domain IG, anti-IL13;IL4 therapeutic antibody, Anti-IL-13/P600;BCGF-1/BCGF1/BSF-1/BSF1/IL-4 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-492
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Romilkimab biosimilar, Bispecific Dual Variable Domain IG, Anti-IL13;IL4 Antibody: Anti-IL-13/P600;BCGF-1/BCGF1/BSF-1/BSF1/IL-4 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Romilkimab (SAR156597), however, ¡°is an engineered, humanised, bispecific immunoglobulin-G4 antibody that binds and neutralizes IL-4/IL-13 making it ideal for exploration in fibrosis,¡± the researchers explain.
| Products Name (INN Index) | Pre-Made Romilkimab biosimilar, Bispecific Dual Variable Domain IG, Anti-IL13;IL4 Antibody: Anti-IL-13/P600;BCGF-1/BCGF1/BSF-1/BSF1/IL-4 therapeutic antibody |
|---|---|
| INN Name | Romilkimab |
| Target | IL13,IL4 |
| Format | Bispecific Dual Variable Domain IG |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa,Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2017 |
| Year Recommended | 2018 |
| Companies | Sanofi |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Idiopathic pulmonary fibrosis,Systemic scleroderma |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | IL13,IL4 |
| Package |
Previous slide
Next slide
